Skip to main content
. 2015 Aug 7;13(8):5016–5058. doi: 10.3390/md13085016

Figure 3.

Figure 3

(A) Plasma Cmax versus dose following a 1-h infusion of eribulin on day 1; (B) Plasma area under the concentration-time curve (AUC)(0–∞) versus dose following a 1-h infusion of eribulin on day 1; (C) Plasma concentration versus time profile for the 1.0 mg/m2 treatment group (n = 9) [50].